As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Köp den här e-boken och få 1 till GRATIS!
Formatera PDF ● Sidor 444 ● ISBN 9781466579705 ● Utgivare CRC Press ● Publicerad 2013 ● Nedladdningsbara 6 gånger ● Valuta EUR ● ID 2715426 ● Kopieringsskydd Adobe DRM
Kräver en DRM-kapabel e-läsare